Doublet Shows Activity in Rare, Aggressive Kidney Cancer

(MedPage Today)-Bevassomab showed a activity in patients with patients with genetic cells and renal cells (HLRCC)-associated with excessive or sporadic papillary cells or renal cell cancer (RCC).